
AngioDynamics (ANGO) Stock Forecast & Price Target
AngioDynamics (ANGO) Analyst Ratings
Bulls say
AngioDynamics Inc. is experiencing notable growth in its Auryon product line, particularly within outpatient-based laboratories (OBLs) and hospitals, which is contributing positively to its average selling prices (ASP). The company is on track to enhance its gross margin (GM) to 52.5% by accelerating manufacturing initiatives and benefiting from a favorable shift towards higher-margin Med-Tech revenues. Additionally, ongoing customer acquisition, increased utilization in existing accounts, and successful pricing strategies indicate strong future growth potential for its key products.
Bears say
AngioDynamics, Inc. anticipates $4M-$6M in tariff headwinds, which could negatively impact their financial performance. The company also projects inventory pressures in the second half of fiscal year 2026 due to rising raw material costs, further affecting profitability. Despite a strong performance in capital sales for NanoKnife disposables, these external challenges could undermine future growth and demand for the company's medical devices.
This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.
AngioDynamics (ANGO) Analyst Forecast & Price Prediction
Start investing in AngioDynamics (ANGO)
Order type
Buy in
Order amount
Est. shares
0 shares